Dumb Money Live – Détails, épisodes et analyse

Big Tech just had one of its worst weeks in years. Earnings were mixed, expectations were impossible, and the market punished everyone from AI spenders to chipmakers to SaaS. Today on Dumb Money: Our Worst Market Week Ever — How We Make It Back x2

Meta beat. Microsoft missed. The reactions were extreme.

Today on Dumb Money, we look past the headlines and focus on what Big Tech earnings are actually telling us — especially around cloud usage and AI-driven compute demand.

With Amazon reporting next, we dig into AWS trends and what a reported $50B commitment tied to OpenAI could mean going forward.

Why Amazon earnings matter most right now.

Tesla's Optimus Gen 3 could be the company's biggest bet yet — maybe even bigger than cars. Elon says the new design is "sublime," but can it really deliver on the hype? Today we break down what we know, what's rumor, and what it means for Tesla stock.

Today on Dumb Money, the highly anticipated (and briefly leaked) "New Bing" is expected to be made official on February 7. What does it mean for $MSFT and $GOOG stock?

Today on Dumb Money, we're exploring the best nontraditional investments with Rob Petrozzo, the founder and CEO of Rally. Rally is an online platform that allows people to invest in and trade shares of rare and unique assets such as collectible cars, watches, and other luxury items.

Today on Dumb Money, we're prepping for the Fed on Wednesday and "triple A" earnings form Apple, Alphabet and Amazon on Thursday. But will reduced consumers cutting back on spending kill the rally we've seen so far in 2023?

Today on Dumb Money, the AI revolution has been underway for some time, but the introduction of OpenAI and ChatGPT is taking things to the next level. OpenAI and ChatGPT are two powerful tools that are giving companies the ability to automate processes, create more efficient customer service, and access a wealth of data quickly and accurately. These technologies are already being used by major tech companies such as Microsoft, Oracle, Salesforce, Google, IBM, Intel, AMD and NVIDIA, and they have the potential to revolutionize many industries. Investors should keep an eye on these developments, as there are plenty of opportunities to benefit from OpenAI and ChatGPT technology. So now is the perfect time to learn more and take advantage of this booming industry.

Yes, that was all written by AI.

The FDA is expected to approve Tirzepatide for weight loss sometime this year and we think it could become the best selling drug of ALL TIME. Today on Dumb Money, we'll weigh the data, size-up the opportunity, and give you the skinny on our diet drug investment thesis.

Here are the GLP-1 RA drug makers and their drugs:

Eli Lilly (ticker LLY)

Tirzepatide sold as Mounjaro for diabetes. Weight loss version expected in 2023.

Dulaglutide sold as Trulicity.

Novo Nordisk (ticker NVO)

Semaglutide sold as Ozempic and Rybelsus for diabetes and Wegovy for weight loss.

Liraglutide sold as Victoza for diabetes and Saxenda for weight loss.

Today's FTX bankruptcy filing reveals new information and we reveal the real reason we said "no" to SBF and FTX.

Today on Dumb Money, we're picking stocks that should benefit from an unusually cold winter. Bundle up!